Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559585 · ClinicalTrials.gov registry record · Phase 3
Methotrexate-Inadequate Response Study
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,492
- Enrollment target
NCT00559585 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,492 participants.
The verdict
NCT00559585, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,492 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
Interventions
- DRUG Subcutaneous (SC) Abatacept
- DRUG Intravenous (IV) Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,492 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559585
The ClinicalTrials.gov registry entry for NCT00559585 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,492 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Subcutaneous (SC) Abatacept is the first listed.
NCT00559585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00559585 about?
NCT00559585 is a clinical study titled "Methotrexate-Inadequate Response Study". The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
What is the current status of trial NCT00559585?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,492 participants. The study started on 2008-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00559585?
The interventions under investigation include: Subcutaneous (SC) Abatacept (DRUG), Intravenous (IV) Abatacept (DRUG).
Who is sponsoring clinical trial NCT00559585?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.